M.D. Anderson Cancer Center
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Primary Objectives: * To evaluate PFS in patients randomized to definitive RT followed by pembrolizumab versus definitive RT followed by observation. Secondary Objectives: Secondary Objective #1: * To evaluate overall survival (OS) in patients randomized to definitive RT followed by maintenance pembrolizumab versus definitive RT followed by observation. Secondary Objective #2: * To evaluate time to next line systemic therapy (defined as systemic therapy given after pembrolizumab) in patients randomized to definitive RT followed by maintenance pembrolizumab versus definitive RT followed b…
Inclusion Criteria: In order to be eligible for trial participation, patients must have: 1. The participant provides written informed consent for the trial. 2. Pathologically confirmed diagnosis of RCC with a clear cell component. 3. Be willing and able to undergo biopsy of a lesion planned for definitive RT. If a lesion amenable to SBRT was biopsied prior to enrollment, this material can be used in lieu of a planned biopsy if the tissue is available for review at MD Anderson. 1. Patients may be allowed on this trial without a biopsy if they are deemed medically unfit for biopsy or if th…
Given by vein (IV)
Given by vein (IV)
Arctuva estimate
Verify or correct the compensation shown for this listing.